Brief: Lipella Pharmaceuticals Doses First Patient In Human Study Of Innovative Contrast Agent
05/04/2023 13:56
April 5 (Reuters) - Lipella Pharmaceuticals Inc
LIPO.O :
* LIPELLA PHARMACEUTICALS DOSES FIRST PATIENT IN HUMAN STUDY
OF
INNOVATIVE CONTRAST AGENT
Source text for Eikon: ID:nPnb7FVffa
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lipella Pharmaceuticals
See all newsBrief: Lipella Pharmaceuticals Says Bankruptcy Court Approves Sale And Asset Purchase Agreement On June 4
Brief: Lipella Pharmaceuticals Inc. Files Voluntary Petitions For Relief Under Chapter 11
Brief: Lipella Pharmaceuticals Announces Positive Final Results From Phase 2a Study Of LP-10 In Oral Lichen Planus
Brief: Lipella Pharmaceuticals Announces Delisting From Nasdaq Capital Market
U.S. STOCKS ON THE MOVE-Marriott International, Coty, Carlyle Group